癌症疫苗
免疫系统
CTL公司*
抗原
免疫疗法
癌症免疫疗法
肿瘤抗原
MUC1号
免疫学
医学
癌症研究
免疫
细胞毒性T细胞
接种疫苗
癌症
CD8型
生物
内科学
体外
生物化学
作者
Jiayi Pan,Wuyi Zeng,Jiangtao Jia,Yi Wu Shi,Danni Wang,Jun Dong,Zixuan Fang,Jiashan He,Xinyu Yang,Rong Zhang,Menghua He,Maoping Huang,Bishi Fu,Bei Zhong,Hui Liu
出处
期刊:Vaccines
[Multidisciplinary Digital Publishing Institute]
日期:2022-07-08
卷期号:10 (7): 1092-1092
被引量:2
标识
DOI:10.3390/vaccines10071092
摘要
Dendritic cells (DCs), as professional antigen-presenting cells (APCs), play a key role in the initiation and regulation of humoral and cellular immunity. DC vaccines loaded with different tumor-associated antigens (TAAs) have been widely used to study their therapeutic effects on cancer. A number of clinical trials have shown that DCs are safe as an antitumor vaccine and can activate certain anti-tumor immune responses; however, the overall clinical efficacy of DC vaccine is not satisfactory, so its efficacy needs to be enhanced. MUC1 is a TAA with great potential, and the immune checkpoint PD-L1 also has great potential for tumor treatment. Both of them are highly expressed on the surface of various tumors. In this study, we generated a novel therapeutic MUC1-Vax tumor vaccine based on the method of PD-L1-Vax vaccine we recently developed; this novel PD-L1-containing MUC1-Vax vaccine demonstrated an elevated persistent anti-PD-L1 antibody production and elicited a much stronger protective cytotoxic T lymphocyte (CTL) response in immunized mice. Furthermore, the MUC1-Vax vaccine exhibited a significant therapeutic anti-tumor effect, which significantly inhibited tumor growth by expressing a high MUC1+ and PD-L1+ level of LLC and Panc02 tumor cells, and prolonged the survival of cancer-bearing animals. Taken together, our study provides a new immunotherapy strategy for improving the cross-presentation ability of therapeutic vaccine, which may be applicable to pancreatic cancer, lung cancer and for targeting other types of solid tumors that highly express MUC1 and PD-L1.
科研通智能强力驱动
Strongly Powered by AbleSci AI